So since you can’t legally purchase CBD flower, what alternatives are there? CBD products are still legal provided that they meet the specific UK requirements. Many of the benefits of CBD were demonstrated from CBD oil, so it is possible that legal CBD oil products might give you the effects that you are after.
Punishment for CBD flower possession can range from a low fine to a prison sentence of up to five years and a significant fine.
Because it is illegal to possess CBD flower in the UK, doing so can result in significant legal consequences. Under the Misuse of Drugs Regulations, cannabis is referred to as a “Class B” drug, so it will not result in legal ramifications as severe as “Class A” drugs like heroin or cocaine, but it can still come with some punishments.
CBD flower is the bud of a cannabis or hemp plant that contains high amounts of CBD and low amounts of THC. The flower is dried and cured and is then typically smoked to be consumed, although it can also be used in cooking and in the creation of oil extracts, tinctures, topicals, and vapes.
Legal alternatives to CBD flower
While some forms of CBD can be legally purchased, not all types are allowed in the UK. Since CBD flower is a popular product in many countries, we’ve rounded up everything you need to know about CBD flower and its legality in the UK.
Because CBD is a controlled substance, hemp flower can be persecuted as severely as cannabis as long as it contains restricted cannabinoids like CBD or THC. The amount doesn’t matter, the consequences will be the same if your CBD flower contains a little CBD or a lot, even if it contains no THC.
Unfortunately, there doesn’t seem to be any sign that CBD flower will be made legal for purchase anytime soon. With regulations around CBD production becoming stricter in 2021 with the novel foods certification, the UK does not appear to be moving towards the broad legalisation like that seen in the states.
Legal consequences of possessing CBD flower in the UK
While these regulations do allow for CBD purchases, the problem lies in the fact that stalk, seeds, and fibre of hemp contain very little CBD when compared to the cannabinoid-rich plant flowers and leaves.
By sticking to a reputable provider and managing your dosing properly, it is possible to effectively swap out CBD flower for legal CBD oil.
Numerous other legal requirements apply to dietary supplement products, including requirements relating to Current Good Manufacturing Practices (CGMPs) and labeling. Information about these requirements, and about FDA requirements across all product areas, can be found on FDA’s website.
When this statutory prohibition applies to a substance, it prohibits the introduction into interstate commerce of any food to which the substance has been added unless FDA, in the agency’s discretion, has issued a regulation approving the use of the substance in the food (section 301(ll)(2) of the FD&C Act [21 U.S.C. § 331(ll)(2)]). To date, no such regulation has been issued for any substance.
Ingredients that are derived from parts of the cannabis plant that do not contain THC or CBD might fall outside the scope of this exclusion, and therefore might be able to be marketed as dietary supplements. However, all products marketed as dietary supplements must comply with all applicable laws and regulations governing dietary supplement products. For example, manufacturers and distributors who wish to market dietary supplements that contain “new dietary ingredients” (i.e., dietary ingredients that were not marketed in the United States in a dietary supplement before October 15, 1994) generally must notify FDA about these ingredients (see section 413(d) of the FD&C Act [21 U.S.C. § 350b(d)]). Generally, the notification must include information demonstrating that a dietary supplement containing the new dietary ingredient will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. A dietary supplement is adulterated if it contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that the ingredient does not present a significant or unreasonable risk of illness or injury (see section 402(f)(1)(B) of the FD&C Act [21 U.S.C. 342(f)(1)(B)]).
The agency also has approved Marinol and Syndros for therapeutic uses in the United States, including for the treatment of anorexia associated with weight loss in AIDS patients. Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9- tetrahydrocannabinol (THC) which is considered the psychoactive component of cannabis. Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to THC and is synthetically derived.
Questions and Answers
Information from adverse event reports regarding cannabis use is extremely limited; the FDA primarily receives adverse event reports for approved products. General information on the potential adverse effects of using cannabis and its constituents can come from clinical trials that have been published, as well as from spontaneously reported adverse events sent to the FDA. Additional information about the safety and effectiveness of cannabis and its constituents is needed. Clinical trials of cannabis conducted under an IND application could collect this important information as a part of the drug development process.